Western Blotting Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics), End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies) - Global Forecasts to 2021

The western blotting market is projected to reach USD 730.7 million by 2021 from USD 574.8 million in 2016, at a CAGR of 4.9% in the next five years (2016 to 2021).
The western blotting market is undergoing a significant transformation, with the automation of blotting systems and imagers. Furthermore, it is one of the most basic technologies for the separation of proteins and is seen at almost every protein research laboratories. The growth of this market is majorly influenced by the dynamics of the protein research industries.
The increasing number of research activities and R&D spending by pharmaceutical and biotechnology companies, rising prevalence of HIV/AIDS, growing proteomics market, the growing number of industry-academic research collaborations, increasing demand for personalized medicine, and new product launches are some factors expected to drive the growth of the global western blotting market in the coming years. On the other hand, emergence of alternative technologies is expected to restrain the growth of the market. However, automation in western blotting instruments is expected to pose lucrative opportunities for the western blotting market. Furthermore, stringent regulations and requirement of high procedural efficiency for accurate results are likely to challenge the western blotting market in the coming years.
In 2016, North America is expected to account for the largest share of the global western blotting market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America’s large share is attributed to the increasing prevalence of HIV and Lyme disease, U.S. –China collaborative program for biomedical research, rise in research funding & increasing production of genetically modified crops in the U.S., HIV vaccine initiative, and Growing intensity of pharmaceutical and biopharmaceutical clinical research in Canada. In the coming years, the western blotting market is expected to witness the highest growth in the Asia-Pacific region, with emphasis on India, China, and Japan. This can be attributed to factors such as presence of bioclusters in China and India, outsourcing of research activity in China, increasing government interest in biomedical & biotechnology industry in China, government initiatives supported by funding in Japan, growing pharmaceutical & biotechnology industry in Japan, growing pharmaceutical industry backed by government funding in India, and growing funding for agriculture research in India.
The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (expansions; new product launches; marketing and promotion; agreements, collaborations, partnerships, and joint ventures; funding; acquisitions; and product enhancement to increase their market shares and establish a strong foothold in the global market.
In-depth interviews were conducted with CEOs, Sales and Marketing Directors, other innovation and technology directors, and executives from various key organizations operating in the adaptive security market place.
? By Company Type: Tier 1: 50%, Tier 2: 35%, Tier 3: 15%
? By Designation: Director Level: 53%, C-Level: 28%, Others: 19%
? By Region: North America: 35%, Europe: 25%, APAC: 28%, ROW: 12%
The report includes the study of key players offering western blotting such as Bio-Rad Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), GE Healthcare (U.S.), Advasta, Inc. (U.S.), LI-COR Biosciences (U.S.), PerkinElmer, Inc. (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Cell Signaling Technology, Inc. (U.S.).

Research Coverage:
The report provides a picture on western blotting instruments and consumables across different applications and regions. It aims at estimating the market size and future growth potential of this market across different segments such as product, application, end user, and regions. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them the closest approximations of the revenue numbers for the overall western blotting market and the subsegments. This report will help stakeholders to better understand the competitor landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. The report also helps the stakeholders to understand the pulse of the market and provides them information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 RESEARCH METHODOLOGY STEPS 20
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 21
2.2.1 SECONDARY RESEARCH 21
2.2.1.1 Key data from secondary sources 21
2.2.2 PRIMARY RESEARCH 22
2.2.2.1 Key data from primary sources 24
2.2.2.2 Key insights from primary sources 24
2.2.2.3 Key industry insights 25
2.3 MARKET SIZE ESTIMATION METHODOLOGY 25
2.4 MARKET DATA VALIDATION AND TRIANGULATION 28
2.5 ASSUMPTIONS FOR THE STUDY 29
3 EXECUTIVE SUMMARY 30
3.1 INTRODUCTION 30
3.2 CONCLUSION 33
4 PREMIUM INSIGHTS 34
4.1 WESTERN BLOTTING: MARKET OVERVIEW 34
4.2 GEOGRAPHIC ANALYSIS: WESTERN BLOTTING MARKET, BY END USER 35
4.3 WESTERN BLOTTING MARKET, BY PRODUCT 36
4.4 WESTERN BLOTTING MARKET, BY APPLICATION 36
4.5 WESTERN BLOTTING MARKET, BY END USER 37
4.6 GEOGRAPHIC SNAPSHOT: WESTERN BLOTTING MARKET 37

5 MARKET OVERVIEW 38
5.1 INTRODUCTION 39
5.1.1 MARKET DRIVERS 40
5.1.1.1 Increasing research activities and R&D spending by pharmaceutical and biotechnology companies 40
5.1.1.2 Rising prevalence of HIV/AIDS 41
5.1.1.3 Growing proteomics market 41
5.1.1.4 Growing number of industry-academic research collaborations 42
5.1.1.5 Increasing demand for personalized medicine 42
5.1.1.6 New product launches 42
5.1.2 MARKET RESTRAINTS 43
5.1.2.1 Emergence of alternative technologies 43
5.1.3 MARKET OPPORTUNITIES 44
5.1.3.1 Automation in western blotting instruments 44
5.1.3.2 Emerging economies to offer significant growth opportunities for the western blotting market 44
5.1.4 MARKET CHALLENGES 45
5.1.4.1 Requirement of high procedural efficiency for accurate results 45
5.1.4.2 Stringent regulations 45
6 GLOBAL WESTERN BLOTTING MARKET, BY PRODUCT 46
6.1 INTRODUCTION 47
6.2 CONSUMABLES 49
6.2.1 REAGENTS 50
6.2.2 KITS 51
6.2.3 OTHER CONSUMABLES 52
6.3 INSTRUMENTS 55
6.3.1 GEL ELECTROPHORESIS INSTRUMENTS 56
6.3.2 BLOTTING SYSTEMS 57
6.3.2.1 Wet Blotting Systems 58
6.3.2.2 Semi-dry Blotting Systems 59
6.3.3 IMAGERS 60
6.3.3.1 Chemiluminescent Imagers 61
6.3.3.2 Fluorescent Imagers 62
6.3.3.3 Other Imagers 63
7 WESTERN BLOTTING MARKET, BY APPLICATION 64
7.1 INTRODUCTION 65
7.2 BIOCHEMICAL & BIOMEDICAL RESEARCH 66
7.3 DISEASE DIAGNOSTICS 67
7.4 AGRICULTURE 68
7.5 OTHER APPLICATIONS 69
8 WESTERN BLOTTING MARKET, BY END USER 70
8.1 INTRODUCTION 71
8.2 ACADEMIC AND RESEARCH INSTITUTES 72
8.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 73
8.4 DIAGNOSTIC LABORATORIES 74
8.5 OTHER END USERS 75
9 WESTERN BLOTTING MARKET, BY REGION 76
9.1 INTRODUCTION 77
9.2 NORTH AMERICA 78
9.2.1 U.S. 82
9.2.1.1 Increasing prevalence of HIV and Lyme disease 82
9.2.1.2 U.S.-China collaborative program for biomedical research 82
9.2.1.3 Rise in research funding and increasing production of genetically modified crops 82
9.2.1.4 Conferences, meetings, and symposiums 83
9.2.2 CANADA 87
9.2.2.1 HIV vaccine initiative 87
9.2.2.2 Growing intensity of pharmaceutical and biopharmaceutical clinical research 87
9.3 EUROPE 91
9.3.1 EUROPE-5 95
9.3.1.1 Strong academic and research base in Germany 95
9.3.1.2 Availability of research funding in the U.K. 95
9.3.1.3 Growth in the Spanish biotechnology industry 95
9.3.2 ROE 98
9.3.2.1 High presence of pharmaceutical and biotechnology companies 98
9.3.2.2 Conferences, workshops, and congresses on western blotting application areas 99
9.4 ASIA-PACIFIC 102
9.4.1 CHINA 106
9.4.1.1 Increasing government interest in biomedical and biotechnology industry 106
9.4.1.2 Presence of bioclusters in China 106
9.4.1.3 Outsourcing of clinical research activity to China 107
9.4.2 JAPAN 110
9.4.2.1 Government initiatives supported by funding 110
9.4.2.2 Growing pharmaceutical and biotechnology industry in Japan 110
9.4.3 INDIA 113
9.4.3.1 Growing pharmaceutical industry in India, backed by government initiatives 113
9.4.3.2 Development of bioclusters 114
9.4.3.3 Growing funding for agriculture research in India 114
9.4.4 ROAPAC 118
9.4.4.1 Korea-U.S. Free Trade Agreement (KORUS) 118
9.4.4.2 Increasing diagnosis of HIV and related funding in Australia 118
9.4.4.3 Growing prevalence of herpes simplex virus in Southeast Asia 118
9.5 ROW 121
9.5.1 RISING PREVALENCE OF HIV IN THE MIDDLE EAST AND AFRICA 122
9.5.2 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON AFRICA 122
9.5.3 PRESENCE OF LARGE END-USER BASE IN BRAZIL 122
10 COMPETITIVE LANDSCAPE 126
10.1 OVERVIEW 126
10.2 MARKET SHARE ANALYSIS 126
10.2.1 INTRODUCTION 126
10.2.2 BIO-RAD LABORATORIES, INC. (U.S.) 127
10.2.3 THERMO FISHER SCIENTIFIC, INC. (U.S.) 127
10.2.4 GE HEALTHCARE (U.S.) 128
10.3 COMPETITIVE SITUATION AND TRENDS 129
10.3.1 PRODUCT LAUNCHES 130
10.3.2 ACQUISITIONS 131
10.3.3 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 132
10.3.4 EXPANSIONS 133
10.3.5 OTHERS 134
11 COMPANY PROFILES 135
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 INTRODUCTION 135
11.2 BIO-RAD LABORATORIES, INC. 136
11.3 THERMO FISHER SCIENTIFIC, INC. 139
11.4 GE HEALTHCARE 142
11.5 ADVANSTA INC. 145
11.6 LI-COR BIOSCIENCES 147
11.7 PERKINELMER, INC. 149
11.8 BIO-TECHNE CORPORATION 151
11.9 F. HOFFMANN-LA ROCHE LTD. 155
11.10 MERCK KGAA 157
11.11 CELL SIGNALING TECHNOLOGY 159

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

12 APPENDIX 160
12.1 DISCUSSION GUIDE 160
12.2 OTHER DEVELOPMENTS 163
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 165
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 167
12.4.1 FEATURES AND BENEFITS OF RT: 167
12.5 AVAILABLE CUSTOMIZATION 167
12.5.1 PORTFOLIO ANALYSIS 167
12.5.2 COMPANY INFORMATION 167
12.6 RELATED REPORTS 168
12.7 AUTHOR DETAILS 169